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Abstract Current genetic counselling practice for Lynch
syndrome (LS) relies on diagnosed index patients to inform
their biological family about LS, referred to as the family-
mediated approach. The objective of this studywas to evaluate
this approach and to identify factors influencing the uptake of
genetic testing for LS. In 59 mutation carriers, 70 non carriers
and 16 non-tested relatives socio-demographic characteristics,
family communication regardingLS, experiences andattitudes
towards the family-mediated approach and motivations for
genetic testing, were assessed. Themajority of all respondents
(73 %) were satisfied with the family-mediated approach.
Nevertheless, 59 % of the respondents experienced informing
a family member and 57 % being informed by a family
member as burdensome. Non-tested differed from tested
respondents, in that they were younger, less closely related to
the indexpatient anda lower proportionhadchildren.Themost
important reasons for declining genetic testing were (1)
anticipating problems with life insurance and mortgage, (2)
being content with life as it is, and (3) not experiencing any
physical complaints. In conclusion, the majority of respon-
dents consider the current family-mediated information pro-
cedure acceptable, although theprovisionof informationonLS
by relatives may be burdensome. Special attention should be
paid to communication of LS to more distant relatives.
Keywords Lynch syndrome  Genetic testing  Family
communication  Motivation
Introduction
Lynch syndrome (LS) is a hereditary condition which pre-
disposes to colorectal cancer, endometrial cancer and other
cancers [1, 2]. It is caused by inherited germline mutations in
mismatch repair (MMR) genes MLH1, MSH2, MSH6 and
PMS2 or the EPCAM gene [3–8]. LS carriers have an
increased cumulative lifetime risk for colorectal cancer of
25–70 %, while women with LS carry a lifetime risk to
develop endometrial cancer of 13–65 % [9–20]. In addition,
LS carriers have an increased risk for cancers of the stomach,
ovaries, small bowel, urinary tract, skin and brain [21–24].
Genetic testing for LS is available to all family members
of a mutation carrier. Genetic testing can have medical and
psychological advantages, irrespective of the outcome in an
individual subject. Non-carriers may avoid unnecessary
surveillance programs for LS and experience relief from
worries about developing cancer both for themselves and
their children. For carriers, genetic testing can lead to relief
from uncertainty and guide screening recommendations,
improving survival through early detection [21, 25]. Despite
the potential benefits of genetic testing, a Dutch study on the
interest in genetic testing for hereditary colorectal cancer
syndromes showed that almost half of the subjects in this
cohort of family members at risk did not opt for genetic
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testing for LS at a median follow-up time after identification
of the family specific mutation of 82 months, ranging
10–140 months [26].
In theNetherlands the communication regardingpresence of
a LS gene mutation within a family occurs by means of the
family-mediated approach. When a pathogenic mutation is
detected the counselee is asked to inform all at risk relatives.
During the counselling process, communication strategies to
inform relatives are discussed with the counselee. Furthermore
a letter to inform relatives is supplied. This approach implies
that familymembers are responsible to inform their relatives on
the diagnosis of LS and the possibility of genetic testing. Cur-
rently, little is known about patients’ experiences with and
attitudes towards this family-mediated approach [27]. Knowl-
edge on the experiences and challenges with regards to
informing family members may help to improve counselling
procedures. A previous US study on family communication of
LS genetic test results showed that most individuals who
undergo genetic testing for LS share their test result with first
degree relatives, while more distant relatives are reached less
often [28]. Interestingly, a Finnish study on family communi-
cation of LS-genetic testing results showed a significant gender
difference. Men were less likely to communicate the diagnosis
of LS to their relatives, yet disclosed this result significantly
more often via a support person such as a spouse [29]. A pre-
vious qualitative study in theNetherlands among30 individuals
fromLS families showed that motivation to disclose seemed to
increase if there were more cancer cases in the family. Dis-
rupted family relationswere found to be an important reason for
non-disclosure. The way family members communicate about
LS may also influence whether or not at-risk family members
decide to opt for genetic testing [30, 31]. It would be of clinical
interest to gain more insight into the factors influencing the
decision whether or not to opt for genetic testing. However,
clinical information about the group of non-tested individuals
for LS is lacking, since individuals who do not opt for genetic
testing often do not apply for genetic counselling.
The aims of this study were to (1) evaluate experiences
and attitudes towards a family-mediated approach in an LS
cohort, (2) compare tested (mutation carriers and non-
carriers) and non-tested individuals on demographic char-
acteristics, anxiety, cancer worry, medical history, family
communication, experiences and attitudes towards the
family mediated approach, and (3) explore the motivations
for uptake or decline of genetic testing for LS.
Methods
Subjects and procedure
We conducted a cross-sectional survey among individuals
with a personal or family history of LS. The study was
performed at the Department of Clinical Genetics of the
Erasmus MC University Medical Center. Subjects were
recruited from a cohort of 40 LS families with a proven LS
mutation. All individuals were 25 years or older, since it is
recommended to undergo genetic testing after this age. The
tested individuals had received their genetic test result
between 1995 and 2009. For each individual a family
pedigree was available with detailed medical information.
Two hundred ninety seven tested individuals C25 years
of age, including index patients, from the above described LS
cohort were notified about the start of the research project by
an advanced notification letter. Individuals who were inter-
ested in participating were asked to respond via a reply card
and were subsequently contacted by de study coordinator.
The study coordinator informed the individual about the
study and asked the individual to participate in this survey. In
addition, the study coordinator specifically asked the tested
individuals if they knew family members who had refrained
from genetic testing for LS. The tested individuals were
asked to contact these non-tested familymembers, in order to
obtain consent for being approached for research purposes.A
questionnaire was sent to all individuals who consented to
participate. Individuals who did not return the questionnaire
after two follow-up telephone calls and two additional
mailings were considered non-responders.
This study was approved by the Institutional Review
Board of The Erasmus MC, and written informed consent
was obtained from all respondents.
Measures
The self-reported questionnaire addressed socio-demo-
graphic characteristics including age, gender, marital sta-
tus, number of children, level of education, employment
and medical characteristics.
In addition, respondents were asked whether they,
themselves or their relatives had ever been diagnosed with
cancer, and to indicate the degree of relatedness to the
closest relative affected by cancer. Medical data of tested
respondents was cross-checked with their family pedigree
at the Department of Clinical Genetics.
Family communication regarding LS was evaluated by a
list of questions developed by the authors after a literature
search [30, 32–34]. Respondents were asked who informed
them about LS, when they were informed, in which way
and how the contact was before en after disclosure of the
LS diagnosis. Furthermore we asked if it was burdensome
to be informed and/or informing relatives on LS using a
five-point Likert scale with response options ranging from
1 ‘very burdensome’ to 5 ‘not burdensome’.
Attitude towards the family mediated approach was
measured by a self-developed questionnaire with two
statements regarding moral duty to disclose LS diagnosis
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and two questions where respondents was asked if they
were satisfied with the current family mediated approach.
These two questions had multiple response options
including ‘‘other’’.
Anxiety and depression were measured by the Hospital
Anxiety and Depression scale (HADS). Seven items of the
HADS reflect anxiety and seven reflect depression.
Response options range from 0 to 3 [35]. The sum on each
subscale indicates the overall anxiety and depression score
(between 0 and 21). A sum score of 11 or more is the
threshold for clinical anxiety.
We assessed concerns regarding cancer by means of the
cancer worry scale (CWS) [36]. The CWS is a four-item
scale that measures worries about the risk of developing
cancer and the impact of worries on daily functioning
(frequency of thoughts of developing cancer, impact of
thoughts about cancer on mood, impact of thoughts about
cancer on daily activities, and level of concern for devel-
oping cancer). Each item has four possible responses (from
1 ‘not at all’, to 4 ‘almost all the time/very concerned’),
which are summed to create a CWS between 4 and 16. A
higher score indicates more concerns regarding cancer.
Motivation for genetic testing was evaluated using a list
of 15 reasons for non-participation, which was adapted
from literature [37, 38]. Non-tested respondents were asked
to rate to what extent they agreed with these reasons for
non-participation in genetic testing on a five-point Likert
scale with response options ranging from 1 ‘totally dis-
agree’ to 5 ‘totally agree’. An open field was included to
add another reason for non-participation.
The questionnaire was pilot tested among ten LS carriers
visiting the outpatient clinic.
Statistical analysis
Categorical variables were used to calculate proportions
and interquartile ranges. The association between cate-
gorical variables was examined by means of the Chi
squared test or Fisher’s exact test. For ordered categorical
variables, the Mann–Whitney test was used. Scores from
the HADS and cancer worry were treated as continuous
variables. For continuous variables the mean and standard
deviation was calculated. These variables were tested using
the independent sample T test. Respondents with missing
data were omitted from the respective analyses.
Mutation carriers, non-carriers and non-tested respon-
dents were compared on socio-demographic characteris-
tics, anxiety, cancer worry, medical history, family
communication, experiences and attitudes towards the
family mediated approach. SPSS 17.0 statistical package
was used to analyse data. All p values are two-sided and a
p value of\0.05 was considered significant.
Results
Subject characteristics
Two hundred ninety seven eligible individuals were
approached for enrolment by an advanced notification let-
ter with reply card. Of these, 215 (72 %) agreed to be
contacted by phone (Fig. 1). Of the 215 subjects who
agreed to be contacted, 177 (60 %) accepted to receive the
questionnaire. One-hundred and twenty-nine (43 %) tested
individuals from 33 LS families returned the questionnaire.
A total of 41 non-tested individuals were contacted via the
tested individuals and 18/41 (44 %) non-tested individuals
returned the questionnaire. Two non-tested individuals
were excluded, since they underwent genetic testing before
completing the questionnaire.
There was no difference in age and gender between non-
participants, non-responders and responders in the tested
and non-tested group (data not shown).
Baseline characteristics of all 145 respondents are
shown in Table 1. Of all 129 tested respondents, 59 (46 %)
were mutation carriers and 70 (54 %) had no LS mutation.
The mean age of mutation carriers was 52 years (SD 14)
and for non-carriers 67 years (SD 13). Both mutation car-
riers and non-carriers were older than non-tested respon-
dents with a mean age of 42 years (SD 17, p = 0.007).
Twelve respondents from the 33 LS families were index
patients.
LS mutation carriers and non-carriers compared
with non-tested respondents
Demographic and family characteristics of mutation car-
riers, non-carriers and non-tested respondents are shown in
Table 1. Non-tested respondents differed from LS mutation
carriers and non-carriers in age, number of children, degree
of relatedness to the index patient and cancer diagnosis. Of
non-tested respondents 44 % did not have children, com-
pared to 14 % of mutation carriers (p = 0.013) and 7 % of
non-carriers (p = 0.02).
Twelve (8 %) respondents had been index patients
within their family and thus the first informed on LS in the
family. Fifty-four respondents (37 %) were first-degree
relatives of the index patients and 78 (53 %) were second
or third-degree relative of the index patient. More non-
tested respondents (63 %) were second-degree relatives of
the index patient, compared to mutation carriers (42 %,
p = 0.03) and non- carriers (47 %, p = 0.02). A minority
of total respondents (N = 10) were third degree relatives
(Table 1). None of the non-tested respondents reported to
be diagnosed with cancer, while 19 (32 %; p = 0.004) of
the mutation carriers and 11 (16 %; p = 0.116) of the non-
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carriers reported to be diagnosed with cancer. Furthermore,
non-tested family members reported to have a median of
one relative with LS-associated cancer, while tested rela-
tives had a median of two relatives with cancer (p = 0.01).
HADS scores did not differ between non-tested
respondents and LS mutation carriers and non-carriers
(mean HADS respectively 4.0; 4.1; 4.7, Table 1) and are
comparable with the mean HADS scores of the Dutch
general population between 18 and 65 years of age [39].
Fourteen respondents (10 %, six mutation carriers, seven
non-carriers, one non tested respondent) had an anxiety
score C11 and two other respondents (1 %, one non-car-
rier, 1 non-tested) had a depression score C11. Mean worry
about cancer did not differ among mutation carriers, non-
carriers and non-tested respondents (Table 1).
Experiences with the family mediated approach
Table 2 shows the experiences with the family-mediated
approach. A total of 115 of the 145 (79 %) respondents
were informed by a family member about the diagnosis LS
mostly by means of a personal explanation (70/145; 48 %)
and/or the letter provided by the Clinical Genetics
department to the index patient (63/145; 43 %). Interest-
ingly, five of sixteen non-tested respondents reported to be
informed on LS diagnosis by a genetic counsellor. In three
cases it was confirmed in our institutional LS database that
these cases were counselled but refrained from genetic
testing.
The majority of the respondents, who were informed by
a family member about the presence of LS in their family,
were informed by a first degree family member (81/115;
70 %) and most of them (74/115; 64 %) reported to have
good contact with this family member. For most respon-
dents the LS disclosure did not change their contact with
the family member. The majority of respondents informed
by a family member about LS (65/115; 57 %) reported that
they had experienced the process of being informed by a
family member as (moderately) burdensome. Significant
more mutation carriers than non-carriers reported burden
Notification letter with reply card to 
297 tested individuals/ 40 LS families
215 tested individuals/ 40 LS families 
agreed to be contacted by telephone
129/177 (73%) tested respondents/ 40 LS 
families
16/41 (39%) non-
tested respondents 
Tested individuals 
contacted 
41 non-tested relatives/ 10 
LS families
No response (N=48)
No response (N=25)
70/129 (54%) Non LS 
mutation carriers
59/129 (46%)  LS 
mutation carriers
Decided to test for 
LS (N=2)
177 tested individuals/ 40 LS 
families agreed to receive a 
questionnaire
Declined (N=38)
Fig. 1 Flowchart of the study procedure
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due to being informed on the LS diagnosis by a family
member (p = 0.002). Moreover, more mutation-carriers
than non-tested respondents experienced burden while
informing other family members about LS, but this dif-
ference was not significant (p = 0.07).
Seventy-four respondents (51 %) answered they had
informed a relative about LS themselves. The majority (44/
74; 59 %) of these had experienced this as (moderately)
burdensome.
Attitudes towards the family mediated approach
Most respondents (106/145; 73 %) reported to be satisfied
with the current family-mediated approach of communi-
cating LS diagnosis within the family (Table 3). Of the 30
respondents (21 %; 15 mutation carriers; 12 non- carriers;
3 non-tested) who did not agree with the current family
mediated approach, 23 (77 %) respondents preferred being
informed by a medical specialist. The 30 respondents,
disagreeing with current family mediated approach belon-
ged to sixteen LS families. In these sixteen families two till
four family members per family shared the opinion that not
family members but health professionals should inform
relatives about LS diagnosis. Women more often than men
reported that health professionals should inform relatives
(28 vs 14 %).
Furthermore, the majority of the respondents agreed
with the statement that it is the moral duty of healthcare
specialists to inform individuals about LS in their family
(63 %). Also, most respondents agreed that it is the
Table 1 Characteristics of the respondents
Mutation
carriers
% Non
-carriers
% Non tested
respondents
% Total
respondents
%
Number of respondents 59 70 16 145 100
Male 26 44 24 34 6 38 56 39
Mean age (±SD)* 52 (14) 67 (13) 42 (17) 55 (15)
Marital status
Single 5 8 7 10 3 19 15 10
(As) married 46 78 53 76 9 56 108 74
Divorced/separated/widowed 7 12 8 11 4 25 19 13
Missing 2 3 1 1 0 0 3 2
Number of children
None* 8 14 5 7 7 44 20 14
One or more children* 51 86 65 93 9 56 125 86
Employed
Yes 38 64 30 43 10 63 78 54
Retired* 12 20 27 39 2 13 41 28
Student 1 2 1 1 1 6 3 2
Missing 2 3 2 3 0 0 4 3
Education
High educational level 24 41 20 29 6 38 50 34
Low educational level 32 54 47 67 10 63 89 61
Missing 3 5 3 4 0 0 6 4
Relation to index
Index patient 9 15 3 4 0 0 12 8
First degree relative* 24 41 27 39 3 19 54 37
Second degree relative* 25 42 33 47 10 63 68 47
Third degree relative 1 2 7 10 2 13 10 7
Cancer diagnosis
Yes* 19 32 11 16 0 0 30 21
Anxiety and cancer worry
Mean cancer worry (±SD) 5.3 (1.4) 5.2 (1.5) 5.1 (1.2) 5.1 (1.4)
HADS anxiety (±SD) 4.1 (3.5) 4.7 (3.6) 4.0 (3.3) 4.5 (3.5)
Median number of relatives with LS cancers* 2 2 1* 2
* p =\ 0.05, non-tested respondents vs LS mutation carriers and non-carriers
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Table 2 Experiences with the family-mediated approach
Mutation
carriers
% Non
carriers
% Non- tested
respondents
% Total
respondents
%
2a. Communication within the family, answered by all respondents
Number of respondents 59 100 70 100 16 100 145 100
When were you informed about LS in your family?
\1 week after diagnosing LS in a family member 20 34 18 26 3 19 41 28
\1 month after diagnosing LS in a family member 8 14 13 19 3 19 24 17
\6 months after diagnosing LS in a family member 3 5 11 16 1 6 15 10
\1 year after diagnosing LS in a family member 3 5 10 14 0 0 13 9
\5 years after diagnosing LS in a family member 6 10 3 4 3 19 12 8
[5 years after diagnosing LS in a family member 2 3 1 1 0 0 3 2
Missing 17 29 14 20 6 37 37 26
Informed on the diagnosis of LS in the family by…(multiple answers)
Family member 41 – 61 – 13 – 115 –
Clinical geneticist/counsellor 31 – 17 – 5 – 53 –
Missing 7 – 0 – 0 – 7 –
Communication tools within the family (multiple answers)
Family information letter genetics 24 – 34 – 5 – 63 –
Personal letter from a family member 6 – 12 – 0 – 18 –
Personal explanation from a family member 25 – 34 – 11 – 70 –
Missing 4 – 2 – 0 – 6 –
2b. Experiences on being informed by a relative about LS
Questions are answered by family members who answered to be informed by a relative about LS
Number of respondents 41 69 61 87 13 81 115 79
Which family member informed you about LS?**
First degree family member 31 75 38 62 12 92 81 70
Second degree family member 6 15 6 10 1 8 13 11
Third degree relative 4 10 17 28 0 0 21 18
Missing 0 0 0 0 0 0 0 0
Contact with the informing family member**
Poor 6 15 13 21 3 23 22 19
Neutral 5 12 12 20 0 0 17 15
Good 29 71 35 57 10 77 74 64
Missing 1 2 1 2 0 0 2 2
Effect on family relations**
Family relations improved 4 10 3 5 1 8 8 7
Family relations worsened 2 5 0 0 1 8 3 3
No change in family relations 34 83 55 90 9 69 98 85
Missing 1 2 3 5 2 15 6 5
Burdensome being informed by family members**,a
Burdensome* 14 34 4 7 1 8 19 17
Moderately burdensome 16 39 24 39 6 46 46 40
Not burdensome 11 27 30 49 6 46 47 40
Missing 0 0 3 5 0 0 3 3
2c. Experiences on informing relatives about LS.
Questions are answered by respondents who answered to have informed a relative or relatives about LS
Did you inform a family member about the diagnosis of LS in your family
Yes 35 56 35 47 4 25 74 51
No 24 41 32 46 12 75 68 47
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personal duty of LS family members to inform relatives
about LS (82 %) However, significantly more of the
non-tested respondents did not agree that it is the per-
sonal duty of tested individuals to inform the family
about the LS diagnosis in their family compared to
tested respondents (13 % of non-tested respondents vs
2 % of mutation carriers and 3 % of non- carriers,
p = 0.004).
Table 2 continued
Mutation
carriers
% Non
carriers
% Non- tested
respondents
% Total
respondents
%
Missing 0 0 3 7 0 0 3 2
Number of respondents 35 59 35 50 4 25 74 51
Burdensome to inform family members***,a
Burdensome 10 28 5 14 1 25 16 22
Moderately burdensome 16 46 11 32 1 25 28 38
Not burdensome 9 26 19 54 2 50 30 40
Missing 0 0 0 0 0 0 0 0
a Converted to 3-point Likert scale
* p =\ 0.05, LS mutation carriers vs non-carriers
** Answered by respondents who answered to be informed by a relative about LS
*** Answered by respondents who answered to have informed a relative about LS
Table 3 Attitudes towards the family-mediated approach
Mutation
carriers
% Non -
carriers
% Non tested
respondents
% Total
respondents
%
Do you think another way of informing relatives on
Lynch syndrome is needed?
No, current procedure is sufficient 41 69 54 77 11 69 106 73
Yes 15 25 12 17 3 19 30 21
I would have liked to receive no information about LS 1 2 1 1 1 6 3 2
Missing 2 3 3 4 1 6 6 4
Respondents who did not agree with the current procedure,
suggested to be informed by:
Medical specialist at the hospital 15 100 12 100 3 100 30 100
General practitioner 12 80 9 75 2 67 23 77
Family meeting 1 7 1 8 1 33 3 10
Opinion of all respondents towards statement I: 2 13 2 17 0 0 4 13
It is the personal duty of LS mutation carriers to inform
one’s family members
Disagree* 1 2 2 3 2 13 5 3
Neutral 7 12 7 10 5 31 19 13
Agree* 51 86 59 84 9 56 119 82
Missing 0 0 2 3 0 0 2 1
Opinion of all respondents towards statement II:
It is the moral duty of physicians to inform patients
in case of Lynch syndrome in their family
Disagree 6 10 12 17 4 25 22 15
Neutral 14 24 9 13 1 6 24 17
Agree 35 59 46 66 11 69 92 63
Missing 4 7 3 4 0 0 7 5
* p =\ 0.05, non-tested respondents vs LS mutation carriers and non-carriers
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Motivation for genetic testing for LS
The most important reasons for genetic testing were: (1)
availability of surveillance programs for LS (61 %), (2)
preference to end insecurity regarding LS diagnosis (34 %),
and (3) fear for cancer (14 %, Table 4). The three most
important reasons for declining genetic testing by non-tested
respondents were: (1) worry that testing would lead to
problemswith life insurance andmortgage (50 %), (2) being
content with life as it is (44 %), and (3) not experiencing any
physical complaints (37 %, Fig. 2). Fear for surveillance
programs was reported in 19 % of non-tested respondents.
Discussion
In this cross-sectional survey among 145 individuals from
LS families, we evaluated the current family-mediated pro-
cedure for informing at risk relatives about the identified
familial LS mutation. Although the majority of the respon-
dents were satisfied with the current family-mediated
approach of communicating LS diagnosis within the fami-
lies, we found that a majority of the respondents (57 %)
experienced being informed by a family member as (mod-
erately) burdensome. Moreover, approximately half of the
respondents experienced informing a family member about
Table 4 Motivations for uptake
of genetic testing for LS
(N = 129),[100
Motivation tested respondents Mutation carriers % Non-carriers %
Fear for cancer 8 14 10 14
Availability of surveillance programmes for LS 36 61 21 30
To end insecurity regarding LS diagnosis 20 34 31 44
Other 11 19 9 13
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
…I think the bloodtest is heavy for me
…I am afraid of the influence of the test result on my relationship
…I dont have an elevated risk to develop cancer
…the test does not tell when te condition will emerge
…I have no time to go to the hospital
…I am afraid to lose my job
…I am afraid I cannot cope if I am positive
…I am afraid of the reactions of the children if I am found positive
…I think I already know my chances to develop colorectal cancer
…I was advised by my family not to be tested
…I am too young
…there is no treatment
…my children will be at increased risk if I am positive
…I was advised by my medical doctor not to be tested
…I am participating in Gynecologic surveillance programs
…I dont want to undergo regular gynecological surveillance
…I dont want to undergo regular surveillance colonoscopy
…I am happier not knowing the test result
….I might get in trouble with my health insurance
…I am participating in Colonoscopy surveillance programs
…I am afraid that I will become depressed upon an unfavourable test …
…I dont have any physical complaints
…I am happy with life as it is now
…I might get in trouble with my mortgage and/or life insurance
Agree Neutral Disagree NA
Fig. 2 Motivations of non-tested respondents for not opting for the genetic test for LS (N = 16), NA = not available
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the LS diagnosis as (moderately) burdensome as well. For-
tunately, for the vast majority of respondents being informed
by a family member did not have an adverse impact on the
relationship with that family member.
Twenty-one percent of the respondents would prefer
another way of informing relatives on LS. Most of these
respondents thought family members should be informed
directly by a medical specialist. This percentage is in
agreement with previous results of studies of Aktan-Collan
et al. [29] and Pentz et al. [40], who reported that 25 and
29 %, respectively, would prefer another way of informing
relatives by the family-mediated approach.
We found that half of the respondents who preferred
another way of informing reported that more members in
their family shared this opinion. It may be that family culture
plays a role in person’s preferred method of informing rel-
atives. Families in which communication is less open or in
which family relationships are less intimate may experience
informing relatives about LS as more burdening. In line with
Aktan-Collan et al., we also observed gender differences in
attitude towards informing relatives. We found that women
more often than men reported that health professionals
should inform relatives (28 vs 14 %). Previous studies have
suggested that this fact is related to gender-related roles and
communication patterns in the families. Women tend to be
the most influential persons in the family network, and
therefore may perceive more responsibility for communi-
cation of the diagnosis. Women may be more likely to per-
ceive responsibility while society depicts them as natural
‘carers’ and may be more often the one that communicate
with intimates about emotional topics in general [41, 42].
Another explanation for the finding of more often women
informing family members may be the fact that endometrial
cancer is the second malignancy in LS, which may be more
difficult to discuss by males [29].
Informing all at-risk relatives about LS is of great
importance, in order to enable each family member to
make an informed decision about genetic testing, in par-
ticular because surveillance has proven to reduce morbidity
and mortality from colorectal cancer [43]. Although all
non-tested respondents in the current study were informed
about LS in the family, it has been observed in a recent
study that the LS diagnosis was less likely to be commu-
nicated to distant relatives [28]. Therefore, it is important
to conduct further research on optimal methods to inform
all at-risk family members, including more distant rela-
tives. Decision aids are an innovative strategy for patient
education and proposed to help optimally inform at-risk
relatives and support them in their decision about genetic
testing for LS. Currently, only one study has evaluated a
paper-based decision aid for genetic testing for LS [44].
The results of this randomized trial were promising, since it
has been found that the decision aid, in comparison with a
control pamphlet, lead to lower decision conflict and
increased informed decision making.
Furthermore, we evaluated moral and personal duties
concerning informing relatives. In our study we found that
the majority of the respondents agreed with the statement
that it is the personal duty of LS family members to inform
at risk relatives about LS in the family. On the other hand a
smaller majority agreed that it is the moral duty of
healthcare specialists to inform individuals about LS in
their family. These findings bring up the complexities
associated with current practice, in which the patient is
primarily responsible to inform-at risk family relatives. For
an extensive consideration of the medical, psychological,
ethical and juridical aspects related to this topic, and the
development of the current guidelines for clinical geneti-
cists, we refer to the paper of Menko et al. [45]. The current
guidelines underline the importance of the provision of
written material and psychological support to help the
patient informing family members and to overcome barri-
ers in this potential difficult task.
Noteworthy, significantly more non-tested relatives as
compared to tested relatives did not agree that it is the
personal duty of tested individuals to inform the family
about the LS diagnosis. It would be interesting to conduct
an interview study among non-tested individuals to gain
more insight in their attitudes towards the most optimal
method of being informed about hereditary cancer.
In the current study, all non-tested respondents were
informed about LS in the family and, consequently not being
aware of LS diagnosis was not a reason for refraining from
genetic testing. Reported reasons for refraining from genetic
testing included problems with life insurance and mortgage,
being happywith life as it is and not experiencing any physical
complaints. The first two reasons are in agreement with pre-
vious studies on other hereditary cancer syndromes [38]. In the
Netherlands, insurance companies are restricted in the use of
genetic information of their clients by the Medical Examina-
tionAct., nevertheless, some people encounter problemswhen
applying for insurance. Although this subject is included in the
genetic counselling procedure, there is more need for clear
information for the counselees on this topic. Furthermore, not
experiencing any physical complaintswas a common reason to
refrain from testing in our study, which underlines the
importance of counselling about LS in order to improve
understanding on LS and available surveillance programmes.
Non-tested respondents differed from tested respondents
on several demographic, medical and family characteris-
tics. We found that non-tested respondents were younger
and were less likely to have children than tested respon-
dents. Consistent with this finding, it has been reported that
knowledge about the risk for children is one of the main
reasons for testing [46]. Furthermore, none of the non-
tested respondents were diagnosed with cancer themselves,
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and, compared with tested respondents, had less family
members with LS-associated cancers, and were less closely
related to the index patient. These factors might influence
how one experiences the threat of cancer and, subse-
quently, the urge to participate in genetic testing for LS.
Genetic test decliners may benefit from information and
counselling, even if they decide not to have a predictive
genetic test. Fortunately, non-tested respondents were not
found to be more vulnerable in terms of anxiety or cancer
worries as compared to tested respondents.
Our study had a few limitations. First, the response rate
among tested individuals was high (73 %), however the
response rate among non-tested individuals was only 39 %.
As in other studies, it is very difficult to include non-tested
relatives [47]. Since relatives were asked to contact non-
tested individuals, there may be a selection bias in that
relatives with whom there was more intimate contact were
more likely to be approached. Also, it is possible that non-
tested relatives who cope with the worries about the risk of
LS by avoiding the subject were less likely to participate in
the current study. Nevertheless, this is the first study
focussing on the specific group of non-tested relatives,
which is known to be a very difficult group to approach. It
provides new insight in the characteristics and motivations
of non-tested relatives. Second, further qualitative research
should be done in order to gain a deeper understanding of
family interactions and communication and decision
making about genetic testing for LS.
In conclusion, the current family-mediated procedure is
accepted by the majority of LS family members, although a
substantial proportion experienced burden informing rela-
tives or being informed by relatives about LS. Healthcare
workers should therefore carefully explore how index
patients would experience communicating the LS diagnosis
to family member, and whether a patient would prefer more
involvement of the healthcare workers in informing relatives
about LS, genetic testing and available surveillance pro-
grammes. Special attention should be paid to communication
of LS to more distant relatives. It is important that family
members who refrain from genetic testing are optimal and
adequately informed about their own risks. They should be
aware of the risks for LS, cancer and absence of symptoms in
early stage cancer. Future studies should clarify risk per-
ception of individuals who do not reach genetic services and
the information and support needs of these individuals should
be explored, including (online) decision aids.
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